TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05131022: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Sponsor: Nurix Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 572 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT05131022 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05131022 Rescue Dossier →